Compare PROF & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | DHF |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.4M | 185.7M |
| IPO Year | N/A | N/A |
| Metric | PROF | DHF |
|---|---|---|
| Price | $7.88 | $2.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 231.5K | ★ 451.1K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,297,000.00 | N/A |
| Revenue This Year | $64.23 | N/A |
| Revenue Next Year | $113.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.94 | N/A |
| 52 Week Low | $3.76 | $2.06 |
| 52 Week High | $8.95 | $2.39 |
| Indicator | PROF | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 62.36 |
| Support Level | $7.22 | $2.47 |
| Resistance Level | $8.15 | $2.55 |
| Average True Range (ATR) | 0.56 | 0.02 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 37.86 | 91.67 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.